PDF factsheet
      Z

immune checkpoint inhibition in gastric or gastro-oesophageal junction cancer (advanced) for all type of patients, clinical trials results

nivolumab versus placebo
ATTRACTION-2, 2017
NCT02267343
nivolumab at 3 mg/kg every 2 weeks
versus
placebo
patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimensdouble blind
Japan, South Korea, and Taiwan
pembrolizumab versus nil
KEYNOTE-059,
NCT02335411

versus
pembrolizumab versus paclitaxel
Keynote 061, 2018
NCT02370498
pembrolizumab
versus
paclitaxel
patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine and who had a PD-L1 CPS of 1 or higheropen label

  Options


in first

in second

  Filter